ATAGI shifts Covid vaccine preference

Monovalent Omicron XBB.1.5 Covid-19 vaccines are now the Australian Technical Advisory Group on Immunisation’s (ATAGI’s) preferred option for individuals aged five years and older   ATAGI has updated its guidance regarding the use of Covid-19 vaccinations to boost protection against Omicron subvariants of the XBB.1 and BA.2.8 sub-lineages, which are currently circulating in Australia.   The

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Research Roundup
Next Cost remains a barrier to medicines